BioWorld

June 25, 2007

Targeted Genetics Adds $19.5M To Bank In Private Placement

Gene therapy firm Targeted Genetics Corp. is boosting its cash position through a $19.5 million private placement of 6.7 million shares priced at $2.91 each to fund ongoing development activities. (BioWorld Today) Read More

Dios Looking Upstream Of TNF For Autoimmune Disease Target

Got A New Formulation? But, That's So Obvious!

Distinct Mechanisms For Boron's Anticancer, Anti-Infective Effects

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...